NR2E3 and retinitis pigmentosa 1: Importantly, in our study, we provided evidence showing that a single subretinal injection of the AAV‐delivered CasMINI_v3.1/ge4.1 system in a mouse model of RP could efficiently knockout Nr2e3, achieve therapeutic levels of gene editing, and lead to ERG improvement and structural preservation.